ImmunityBio Falls as Positive ANKTIVA Updates Meet Profit-Taking Pressure

ImmunityBio (IBRX) is down 8.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears to be less about a single negative surprise and more about a sell-the-news reaction. ImmunityBio released favorable ANKTIVA updates this week, but the stock had already run sharply over the past month and recent insider-sale filings may have added pressure.

Details:

On October 14, ImmunityBio said the FDA expanded ANKTIVA plus BCG to cover patients with BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors, broadening the label beyond the earlier carcinoma-in-situ setting.

The company followed with new long-term clinical data on October 16 showing durable responses in QUILT-3.032, including 84% cystectomy-free survival at three years and complete responses extending beyond 53 months.

Those updates were fundamentally positive, so the decline suggests traders may have been locking in gains after a strong run. The stock had risen notably over the last month before today’s drop.

Recent SEC filings also showed insider-related selling activity and planned sales earlier in October, which could have weighed on sentiment even without a fresh negative corporate announcement.

Sources:

ImmunityBio Investor Relations, SEC, Stock Titan

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IBRX Insider Trading Activity

$IBRX insiders have traded $IBRX stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $IBRX stock by insiders over the last 6 months:

CHRISTOBEL SELECKY has made 0 purchases and 3 sales selling 256,200 shares for an estimated $2,310,281.
CHERYL COHEN has made 0 purchases and 2 sales selling 212,266 shares for an estimated $2,098,029.
BARRY J. SIMON has made 0 purchases and 3 sales selling 73,033 shares for an estimated $630,973.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$IBRX Hedge Fund Activity

We have seen 198 institutional investors add shares of $IBRX stock to their portfolio, and 137 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

D. E. SHAW & CO., INC. added 11,551,019 shares (+inf%) to their portfolio in Q2 2026, for an estimated $101,129,171
BLACKROCK, INC. added 7,736,819 shares (+29.4%) to their portfolio in Q2 2026, for an estimated $67,735,850
TWO SIGMA INVESTMENTS, LP added 6,711,606 shares (+153.0%) to their portfolio in Q2 2026, for an estimated $58,760,110
MILLENNIUM MANAGEMENT LLC added 4,159,549 shares (+292.9%) to their portfolio in Q2 2026, for an estimated $36,416,851
HRT FINANCIAL LP removed 3,925,446 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $34,367,279
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,888,607 shares (+inf%) to their portfolio in Q2 2026, for an estimated $25,289,754
TANG CAPITAL MANAGEMENT LLC removed 2,333,333 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $20,428,330

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$IBRX Congressional Stock Trading

Members of Congress have traded $IBRX stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $IBRX stock by members of Congress over the last 6 months:

REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 2 purchases worth up to $30,000 on 09/30, 09/28 and 0 sales.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$IBRX Analyst Ratings

Wall Street analysts have issued reports on $IBRX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 05/21/2026

To track analyst ratings and price targets for $IBRX, check out Quiver Quantitative's $IBRX forecast page.

$IBRX Price Targets

Multiple analysts have issued price targets for $IBRX recently. We have seen 3 analysts offer price targets for $IBRX in the last 6 months, with a median target of $15.0.

Here are some recent targets:

Andres Y. Maldonado from HC Wainwright & Co. set a target price of $15.0 on 06/02/2026
Jeet Mukherjee from BTIG set a target price of $12.0 on 05/21/2026
Jason Kolbert from D. Boral Capital set a target price of $23.0 on 05/05/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.